Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy.
NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
The vice president of pharmacy operations at American Oncology Network discusses the 340B Drug Pricing Program and its growth and impact on community oncology.